Urania Dafni

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


15 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
2024
 
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
Martín-Lluesma S., Svane I.M., Dafni U., Vervita K., Karlis D., Dimopoulou G., Tsourti Z., Rohaan M.W., Haanen JBAG, Coukos G., 2024/10. Annals of oncology, 35 (10) pp. 860-872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C3B84E4D1FD]
Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: A study protocol.
Kinj R., Gaide O., Jeanneret-Sozzi W., Dafni U., Viguet-Carrin S., Sagittario E., Kypriotou M., Chenal J., Duclos F., Hebeisen M. et al., 2024/03. Clinical and translational radiation oncology, 45 p. 100743. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A13C0D7F4DC1]
2023
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03AE420D2700]
 
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N. et al., 2023/01. Lung cancer, 175 pp. 141-151. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39ABDF31542A]
2022
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study.
Meylan S., Dafni U., Lamoth F., Tsourti Z., Lobritz M.A., Regina J., Bressin P., Senn L., Grandbastien B., Andre C. et al., 2021/07/05. BMJ open, 11 (7) pp. e049232. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_471F833F0211]
 
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Peters S., Dafni U., Perol M., Felip E., Polito L., Pal N., Ton T.G.N., Merritt D., Morris S., Stahel R.A., 2021/05. Annals of Oncology, 32 (5) pp. 687-688.
[DOI][WoS][serval:BIB_3634E1D8C4C5]
 
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Dafni U., Martín-Lluesma S., Balint K., Tsourti Z., Vervita K., Chenal J., Coukos G., Zaman K., Sarivalasis A., Kandalaft L.E., 2021/01. European journal of cancer, 142 pp. 63-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D084831A838B]
2020
 
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Molina-Vila M.A., Stahel R.A., Dafni U., Jordana-Ariza N., Balada-Bel A., Garzón-Ibáñez M., García-Peláez B., Mayo-de-Las-Casas C., Felip E., Curioni Fontecedro A. et al., 2020/03. Journal of thoracic oncology, 15 (3) pp. 416-425. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A96B7671FCB]
2019
 
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF9E566FB280]
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_313F7CD9FDBC]
2018
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
Letovanec I., Finn S., Zygoura P., Smyth P., Soltermann A., Bubendorf L., Speel E.J., Marchetti A., Nonaka D., Monkhorst K. et al., 2018/03. Journal of thoracic oncology, 13 (3) pp. 413-425. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_51ABD4101BD9]
2017
 
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R., Dafni U., Felip E., Curioni-Fontecedro A., Gautschi O., Peters S., Massutí B., Palmero R., Aix S.P., Carcereny E. et al., 2017/05. The Lancet. Respiratory medicine, 5 (5) pp. 435-444. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6307005064D]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University